Meeting
2016 ASCO Annual Meeting
Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
Authors
Youjin Kim
Samsung Medical Center, Seoul, Korea, The Republic of
Youjin Kim , Su Jin Lee , Keunchil Park , Se-hoon Lee , Jong Mu Sun , Bhumsuk Keam , Ho Jung An , Jae Yong Cho , Jin-Soo Kim , Ha-young Lee , HyeRyun Kim , Kyoung Eun Lee , Moon Young Choi , Ki Hyeong Lee , Myung-Ju Ahn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT02558387
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6090)
DOI
10.1200/JCO.2016.34.15_suppl.6090
Abstract #
6090
Poster Bd #
412
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).
First Author: Joel Guigay
Poster
2016 ASCO Annual Meeting
Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
First Author: Keith D. Eaton
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen